# CD19-B Cell Depletion in PAIS-ME/CFS Patients

> **NCT07724834** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Charite University, Berlin, Germany** · enrollment: 38 (estimated)

## Conditions studied

- Post-acute Infectious Syndrome (PAIS)
- Post-COVID 19 Condition (PCC or Long COVID)
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

## Interventions

- **DRUG:** Inebilizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07724834
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-01
- **Primary completion:** 2029-02-01
- **Final completion:** 2029-03-01
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07724834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07724834, "CD19-B Cell Depletion in PAIS-ME/CFS Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07724834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*